The KCa2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs-Reference-Cited by-同舟云学术

The KCa2 Channel Inhibitor AP30663 Selectively Increases Atrial Refractoriness, Converts Vernakalant-Resistant Atrial Fibrillation and Prevents Its Reinduction in Conscious Pigs

Published:2020-02-28 Issue: Volume:11 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Diness Jonas Goldin,Kirchhoff Jeppe Egedal,Speerschneider Tobias,Abildgaard Lea,Edvardsson Nils,Sørensen Ulrik S.,Grunnet Morten,Bentzen Bo Hjorth

Funder

Innovationsfonden

Wellcome Trust

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference20 articles.

1. Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs;Bechard;J. Cardiovasc. Pharmacol.,2011

2. Mechanisms of action of the KCa2 negative modulator AP30663, a novel compound in development for treatment of atrial fibrillation in man;Bentzen,2020

3. A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation;Camm;Eur. Heart J. Cardiovasc. Pharmacother.,2019

4. Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation;Christophersen;Nat. Genet,2017

5. Inhibition of small-conductance Ca2+-activated K+ channels terminates and protects against atrial fibrillation;Diness;Circ. Arrhythmia. Electrophysiol.,2010

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards prospective in-silico trials in atrial fibrillation: the case of polypharmacological SK and K2P channel block;2024-03-30

2. In situ monolayer patch clamp of acutely stimulated human iPSC-derived cardiomyocytes promotes consistent electrophysiological responses to SK channel inhibition;Scientific Reports;2024-02-07

3. Therapeutic advances in atrial fibrillation based on animal models;Journal of Zhejiang University-SCIENCE B;2024-02

4. A phase 1 trial of AP30663, a K_Ca2 channel inhibitor in development for conversion of atrial fibrillation;British Journal of Clinical Pharmacology;2024-01-08

5. Inhibition of the KCa2 potassium channel in atrial fibrillation: a randomized phase 2 trial;Nature Medicine;2023-12-13